Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00040690|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : December 19, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia Lymphoma||Biological: filgrastim Drug: cyclophosphamide Drug: cytarabine Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: leucovorin calcium Drug: methotrexate Drug: vincristine sulfate Radiation: radiation therapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Masking:||None (Open Label)|
|Official Title:||A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma|
|Study Start Date :||November 2008|
|Actual Study Completion Date :||December 2008|
- Progression-free survival
- Survival time
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00040690
|Medical Research Council Clinical Trials Unit|
|London, England, United Kingdom, NW1 2DA|
|Study Chair:||Simon Clawson||Medical Research Council|